ACS News

 
 
  • STEMI Latecomers Still Benefit From Coronary Revascularization French observational data show significantly better outcomes with primary PCI than without it in STEMI patients presenting 12 to 48 hours after symptom onset.
  • ESOC 2021 Ticagrelor of Net Clinical Benefit After Stroke, TIA: THALES A new analysis of data from the THALES trial separates out the reduction in ischemic events from the increase in bleeding events and shows the benefit outweighs the risk in a ratio of four-to-one.
  • Blacks With Hypertension Also Seem to Benefit From Amlodipine With Benazepril In hypertensive patients, including Blacks, combining amlodipine, rather than hydrochlorothiazide, with benazepril effectively reduced multiple cardiovascular outcomes, including death, in a post-hoc analysis of the ACCOMPLISH trial.
  • Radiation Exposure During Cardiac Cath on the Decline Radiation exposure associated with diagnostic cardiac catheterization (DCC) has dropped over the past decade, possibly due to technological advances and greater implementation of dose-saving techniques, according to new findings.
  • ESC 2021 New ESC/EACTS Valvular Heart Disease Guidelines New European guidelines for the management of valvular heart disease offer more than 45 revised or completely new recommendations relative to the previous version published in 2017.
  • Open Notes May Help Older Adults — If They Actually Read Them Visit notes help some patients with chronic conditions remember their care plan, but many older patients who could benefit are probably missing out, research suggests.
  • ESC 2021 STOP-DAPT 2 ACS: 1 Month of DAPT Inadequate After Recent ACS Findings from a Japanese trial show 1 month of dual antiplatelet therapy and 11 months of clopidogrel monotherapy is inferior to 12 months of DAPT in patients undergoing PCI after acute coronary syndrome.
  • ESC 2021 Antiplatelets and Anticoagulation Post-PCI: More on MASTER DAPT New analysis from the MASTER DAPT trial of shortened DAPT in high bleeding risk patients focuses on oral anticoagulants, with experts in the field differing somewhat on interpretation of the results.
  • ESC 2021 Seasonal Flu Vax Cuts Post-MI Mortality: IAMI The randomized study's results, along with observational data, "should be sufficient to establish influenza vaccination as a new standard of care as part of in-hospital treatment," researchers said,
  • ESC 2021 STEP: Lowering Blood Pressure Below 130 mm Hg Shows CV Benefit This large Chinese trial in older patients with hypertension confirms the benefit seen with an intensive strategy in SPRINT. But experts warn such low BP levels will not be attainable in all patients.
  • ESC 2021 Saturated Fats From Meat May Increase Cardiovascular Risk The source, not just the intake, of saturated fats may be crucial in determining the impact on cardiovascular disease risk, suggests a UK study that found switching to healthy foods could be beneficial.
  • ESC 2021 FFR Adds No Value to Angiography: RIPCORD 2 In patients with coronary disease undergoing PCI, fractional flow reserve assessment at the time of angiography improves outcome but has no apparent value as a routine study in all CAD patients.
  • ESC 2021 Angiography Can Wait for Cardiac Arrest Without ST-Elevation Results of the TOMAHAWK trial show that immediate transfer for angiography after out-of-hospital arrest without ST-segment elevation provided no mortality advantage over a delayed or more selective approach.
  • ESC 2021 'Less Is More' for Edoxaban in Post-TAVI Anticoagulation: ENVISAGE-TAVI AF Although edoxaban was associated with similar net adverse cardiac events as vitamin K antagonists, it was linked to high rates of major bleeding in this phase 3b study.
  • ESC 2021 MASTER DAPT: 1 Month DAPT Enough After High-Bleeding-Risk PCI The study gives the first prospective randomized evidence for abbreviated dual antiplatelet therapy in this group of patients with high risk for bleeding.
  • Antidepressant, Exercise Help Combat Anxiety in CHD Both escitalopram and exercise may help lower anxiety in adults with coronary heart disease (CHD) and high levels of anxiety ― but escitalopram has the greater impact, new research suggests.
  • SGLT2 Inhibitor Use Rising in Diabetic Kidney Disease 'SGLT2 inhibitors are here to stay as a new standard of care for patients with diabetic kidney disease,' said Dr Katherine Tuttle, a nephrologist at Providence Healthcare in Spokane, Washington.
  • Colchicine Effective Regardless of ACS History, Timing: LoDoCo2 The results contrast with those from another subanalysis, in which greater benefits were observed with earlier administration of the repurposed gout medication.
  • ESC 2021 Eyes on ESC '21: Hope for EMPEROR-Preserved, Guidelines Remade But the Congress will feature far more than, potentially, results the heart failure world has been longing to see and a raft of new guidelines. Also, why it likely isn't the last ESC virtual edition.
  • Mediterranean Diet Slows Progression of Atherosclerosis in CHD Following a Mediterranean diet is more effective in reducing atherosclerosis progression than following a low-fat diet for patients with coronary heart disease (CHD), new research suggests.